Therapy of adult acute leukemia with daunorubicin and L‐asparaginase

Gerald P. Bodey, James S. Hewlett, Charles A. Coltman, Victorio Rodriguez, Emil J. Freireich

Research output: Contribution to journalArticlepeer-review

23 Scopus citations


Fifty‐four adults with acute leukemia resistant to other therapies received treatment with Daunorubicin and L‐asparaginase. Seventeen (31%) achieved complete remission. The complete remission rate was higher among the 31 patients receiving simultaneous therapy than among the 23 patients receiving sequential therapy (42% vs. 17%). Patients with acute lymphocytic leukemia had a higher remission rate than patients with acute myelogenous leukemia (38% vs. 20%). The median duration of complete remission was only 12 weeks, and the median duration of survival for responders was 30 weeks.

Original languageEnglish (US)
Pages (from-to)626-630
Number of pages5
Issue number3
StatePublished - Mar 1974
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Therapy of adult acute leukemia with daunorubicin and L‐asparaginase'. Together they form a unique fingerprint.

Cite this